肿瘤化疗药物心脏毒性的预防策略  

Prevention strategy of cardiotoxicity in cancer chemotherapy

作　　者：韩尽斌 吴宁 花永强 朱福[4] 

机构地区：[1]上海交通大学医学院附属第九人民医院中医科,上海200033 [2]上海市浦东新区公利医院肿瘤科,上海200135 [3]复旦大学附属肿瘤医院中西医结合科,复旦大学上海医学院肿瘤学系,上海200032 [4]上海市徐汇区中心医院心内科,上海200031

出　　处：《中国癌症杂志》2018年第1期75-80,共6页China Oncology

基　　金：国家自然科学基金项目(81473498)

摘　　要：化疗药物的心脏毒性越来越受到关注。在临床实践中,可以通过降低药物剂量、调整给药管理和使用低毒剂型等优化化疗方案对策降低心脏毒性反应的发生率和严重程度。心脏保护剂的应用也非常重要,目前常用的药物包括右丙亚胺、心血管药物和中药制剂等,但这些药物作为心脏保护剂的应用具有局限性,且其有效性和安全性尚需要进一步验证。The cardiotoxicity of chemotherapeutic drugs is receiving more and more attention. The incidence and severity of cardiotoxicity can be reduced by methods such as reducing the dose of drugs, adjusting administration, and using low toxic drugs in clinical practice. Besides, app Lncation of cardioprotective agents is very important and agents including cardiovascular ones, dexrazoxane as well as Chinese medicine preparations are commonly used currently. However, effects of these agents used for cardioprotection during chemotherapy are limited, and their safety needs further verification.

关 键 词：肿瘤-心脏病学 心脏毒性 化疗 右丙亚胺 

分 类 号：R730.53[医药卫生—肿瘤]